Form 4: Jane Henderson Sells Apogee Therapeutics Shares

Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc., reported the sale of 2,000 shares of common stock on April 1, 2026, executed under a Rule 10b5-1 trading plan.

Summary

• Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc., sold a total of 2,000 shares of common stock on April 1, 2026.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on September 2, 2025.
• The shares were sold at weighted average prices: 900 shares at a weighted average of $84.46 and 1,100 shares at a weighted average of $85.46.
• Following these transactions, Henderson beneficially owns 177,371 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the reported stock sales were executed under a pre-established Rule 10b5-1 trading plan, mitigating concerns about insider knowledge influencing the transaction.

Negatives

• Insider selling activity, particularly by a high-ranking executive like the CFO, can sometimes be perceived negatively by the market, although this sale was conducted under a pre-arranged trading plan.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common for executives to diversify holdings or manage personal finances, and are generally viewed as less indicative of negative company outlook compared to discretionary sales. However, the volume and timing relative to company news can still influence market perception.

Stakeholder Impact

• Shareholders: May observe insider selling, but the Rule 10b5-1 plan suggests a pre-determined strategy rather than a reaction to new information, potentially limiting negative sentiment.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Apogee Therapeutics, Jane Henderson, Stock Sale, Beneficial Ownership, CFO